164 related articles for article (PubMed ID: 21637049)
21. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
[TBL] [Abstract][Full Text] [Related]
22. Limitations of FDG-PET and FDG-PET with computed tomography for detecting synchronous cancer in pharyngeal cancer.
Suzuki H; Hasegawa Y; Terada A; Ogawa T; Hyodo I; Suzuki M; Nakashima T; Tamaki T; Nishio M
Arch Otolaryngol Head Neck Surg; 2008 Nov; 134(11):1191-5. PubMed ID: 19015450
[TBL] [Abstract][Full Text] [Related]
23. FDG-PET in 10 children with non-Hodgkin's lymphoma: initial experience in staging and follow-up.
Amthauer H; Furth C; Denecke T; Hundsdoerfer P; Voelker T; Seeger K; Stöver B; Henze G
Klin Padiatr; 2005; 217(6):327-33. PubMed ID: 16307418
[TBL] [Abstract][Full Text] [Related]
24. Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging.
Choi JY; Lee KS; Kwon OJ; Shim YM; Baek CH; Park K; Lee KH; Kim BT
J Clin Oncol; 2005 Oct; 23(30):7654-9. PubMed ID: 16234527
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma].
Thill R; Neuerburg J; Fabry U; Cremerius U; Wagenknecht G; Hellwig D; Osieka R; Günther R; Büll U
Nuklearmedizin; 1997 Oct; 36(7):234-9. PubMed ID: 9441282
[TBL] [Abstract][Full Text] [Related]
26. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
[TBL] [Abstract][Full Text] [Related]
27. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
28. FDG-PET/CT in the evaluation of anal carcinoma.
Cotter SE; Grigsby PW; Siegel BA; Dehdashti F; Malyapa RS; Fleshman JW; Birnbaum EH; Wang X; Abbey E; Tan B; Kodner IJ; Hunt SR; Lowney JK; Mutch MG; Dietz DW; Myerson RJ
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):720-5. PubMed ID: 16626889
[TBL] [Abstract][Full Text] [Related]
29. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
[TBL] [Abstract][Full Text] [Related]
30. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease.
Paes FM; Kalkanis DG; Sideras PA; Serafini AN
Radiographics; 2010 Jan; 30(1):269-91. PubMed ID: 20083598
[TBL] [Abstract][Full Text] [Related]
31. Utility of 18F-FDG PET/CT for staging NK/T-cell lymphomas.
Wu HB; Wang QS; Wang MF; Li HS; Zhou WL; Ye XH; Wang QY
Nucl Med Commun; 2010 Mar; 31(3):195-200. PubMed ID: 20009963
[TBL] [Abstract][Full Text] [Related]
32. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
[TBL] [Abstract][Full Text] [Related]
33. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
[TBL] [Abstract][Full Text] [Related]
34. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
Kumar R; Xiu Y; Zhuang HM; Alavi A
Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
[TBL] [Abstract][Full Text] [Related]
35. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?
Schaefer NG; Hany TF; Taverna C; Seifert B; Stumpe KD; von Schulthess GK; Goerres GW
Radiology; 2004 Sep; 232(3):823-9. PubMed ID: 15273335
[TBL] [Abstract][Full Text] [Related]
36. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.
Newman JS; Francis IR; Kaminski MS; Wahl RL
Radiology; 1994 Jan; 190(1):111-6. PubMed ID: 8259386
[TBL] [Abstract][Full Text] [Related]
37. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
[TBL] [Abstract][Full Text] [Related]
38. The impact of FDG positron emission tomography imaging on the management of lymphomas.
Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL
Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743
[TBL] [Abstract][Full Text] [Related]
39. Positron emission tomography in the detection and staging of ocular adnexal lymphoproliferative disease.
Valenzuela AA; Allen C; Grimes D; Wong D; Sullivan TJ
Ophthalmology; 2006 Dec; 113(12):2331-7. PubMed ID: 16996604
[TBL] [Abstract][Full Text] [Related]
40. Dual-time F-18 FDG-PET/CT imaging for diagnosis of occult non-Hodgkin lymphoma in a patient with esophageal cancer.
Ahmadzadehfar H; Sabet A; Näke K; Hinterthaner B; Biersack HJ; Ezziddin S
Clin Nucl Med; 2009 Mar; 34(3):168-70. PubMed ID: 19352282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]